INTRODUCTION
============

Non-cutaneous melanoma often develops in areas shielded from ultraviolet rays, and its incidence is less than that of cutaneous melanoma. Vaginal malignant melanoma is a rare form of non-cutaneous melanoma, and accounts for only 1.6% of female genital tract melanoma cases. Furthermore, vaginal melanoma accounts for 2.4%-2.8% of all vaginal cancers and 0.3%-0.8% of all malignant melanomas \[[@B1]\], and is the second most common female genital tract melanoma. The age of onset of vaginal melanoma has been reported to range from 38 to 90 years, with most patients being diagnosed between the ages of 60 and 80 years. Most vaginal melanoma patients are postmenopausal, and their primary complaints tend to include vaginal bleeding and vaginal discharge. Unlike melanoma of the skin, vaginal melanomas can be staged according to the International Federation of Gynecology and Obstetrics (FIGO) staging criteria \[[@B2]\]. Unfortunately, vaginal melanomas are often only diagnosed at an advanced stage \[[@B3]\], and treatment options include local excision with wide margins, radical surgery, radiotherapy, chemotherapy, and immunotherapy. Currently, no standard treatment protocol has been established, and the prognosis remains poor, with the 5-year survival rate for vaginal malignant melanoma reported to range from 0% to 25% \[[@B4]-[@B6]\]. The risk factors for vaginal melanoma also remain unclear.

In this study, records from 31 patients with vaginal malignant melanoma diagnosed between March 1970 and June 2005 were retrospectively analyzed to investigate the factors that affect patient prognosis and the most effective treatment strategy for this disease.

MATERIALS AND METHODS
=====================

1. Patient enrollment
---------------------

The clinical records of all patients diagnosed with vaginal malignant melanoma who were treated at the Sun Yat-sen University Cancer Center between March 1970 and June 2005 were reviewed for this study. The histologic type of each case was reassessed by pathologists according to World Health Organization criteria prior to inclusion in the present study. Prior patient consent and approval from the Institutional Research Ethics Committee of Sun Yat-sen University Cancer Center were obtained for the use of clinical materials for this study.

2. Factors for analysis
-----------------------

Macroscopic tumor growth was divided into 3 categories: cauliflower-like, nodular, and ulcerative. Tumor size was evaluated as both a continuous variable and a binary variable (\<4 cm or ≥4 cm). Disease was staged according to the FIGO staging criteria (2009) for vaginal carcinoma. Four types of treatment were administered to patients in this study: surgery followed by immunotherapy, surgery alone, chemotherapy plus immunotherapy, and chemotherapy alone. Radical surgery included hysterectomy, whereas conservative surgery did not.

3. Surveillance after completion of treatment
---------------------------------------------

After primary treatment, patients were followed up every 3 months for the first 2 years, every 6 months for the next 3 years, and annually thereafter. Pelvic ultrasonography was performed annually, and a chest radiograph was also obtained. Other imaging studies (e.g., chest/abdominal/pelvic computed tomography and magnetic resonance imaging) were performed, as clinically indicated.

4. Statistical analysis
-----------------------

SPSS ver. 16.0 (SPSS Inc., Chicago, IL, USA) was used for analysis of data. Patient age, macroscopic tumor growth, tumor size, FIGO staging, radicality of surgery, lymphadenectomy, and treatment method were analyzed using one-way analysis of variance. Two-sided probability values were calculated and were considered significant at the level of p=0.05. Overall survival (OS) was the primary endpoint evaluated, and was calculated from the first day of treatment. When information on survival was not available, an attempt was made to obtain death certificate information. If such information could not be obtained, data after the last contact were censored. OS was calculated using the Kaplan-Meier method. Tumor stage, macroscopic tumor growth, tumor size, radicality of surgery, treatment method, and patient age were also assessed using univariate analysis to determine their impact on OS. Multivariate analysis was performed using the Cox regression method. Hazard ratios with their 95% confidence intervals are reported.

RESULTS
=======

1. Clinical data
----------------

### 1) Patient characteristics

A total of 31 patients with stage I (n=26), stage II (n=3), or stage IV (n=2) primary vaginal melanoma were enrolled in this study. [Table 1](#T1){ref-type="table"} summarizes the characteristics of these patients and their tumors. The median age of the patients was 58 years (range, 18 to 73 years), and most patients presented with vaginal bleeding (n=19), vaginal discharge (n=6), or a vaginal mass (n=4). The median time interval between the onset of symptoms and diagnosis was 3 months (range, 1 month to 36 years). The median duration of follow-up was 20.2 months from the initial treatment (range, 1 month to 18 years).

### 2) Tumor characteristics

All of the vaginal lesions examined were black or grey in color, and most were nodular in shape. Tumor diameters ranged from 0.5 to 7.0 cm, and the majority were localized in the lower third of the vagina. FIGO stage I tumors were diagnosed in 26 cases. For treatment, 9 patients underwent pelvic lymphadenectomy, and 4 of these patients (44%) developed pelvic lymph node (LN) metastases. Five patients underwent resection of the inguinal LNs, and inguinal LN metastasis was found in 2 patients (40%).

2. Treatment methods
--------------------

Although 2 patients did not receive any treatment, 29 received 4 different types of treatment ([Table 2](#T2){ref-type="table"}). Surgery-based treatment was performed for 22 patients, with 11 patients undergoing radical surgery and the other 11 undergoing conservative surgery. LN dissection or biopsy (pelvic and/or inguinal LN) was performed in 12 cases. Neoadjuvant chemotherapy was administered to 6 patients, and 1 patient underwent brachytherapy prior to surgery. Following surgery, 16 patients received chemotherapy and 2 patients underwent chemoradiation therapy. Chemotherapy alone without surgery was used to treat 7 patients, 4 of whom received immunotherapy together with chemotherapy.

Immunotherapy was administered to 19 patients, including regimens of interferon-α (IFN-α), interleukin-2 (IL-2), bacillus Calmette-Guérin (BCG), dendritic cells (DC-cells), lymphokine-activated killer cells (LAK cells), and a measles vaccine.

3. Survival
-----------

The disease recurred in 11 cases, 3 of which (27.3%) involved local recurrence, 7 involved (63.6%) distant recurrence, and 1 involved (9.1%) both local and distant recurrence. However, it should be noted that 2 types of follow-up methods were employed in this study. One group of patients underwent physical examination and/or imaging examination for recurrent disease as scheduled. In contrast, the other group of patients did not come back for examination. These patients were contacted by phone, and their survival was confirmed. However, the exact onset of disease recurrence is unknown. Overall, 8 patients survived and 23 patients died due to tumor progression. The 5-year OS rate was 32.3% for this cohort, and the median survival time was 20.1 months. Characteristics of the 8 patients who survived are listed in [Table 3](#T3){ref-type="table"}.

4. Prognostic factors for survival
----------------------------------

Kaplan-Meier survival analysis revealed that macroscopic tumor growth and the treatment method were factors significantly associated with OS (p=0.039 and p\<0.001, respectively) ([Table 4](#T4){ref-type="table"}). The 5-year OS rates for patients with cauliflower-like, nodular, and ulcerative tumors were 20%, 38%, and 40%, respectively. The 5-year OS rates for patients who were treated with surgery plus immunotherapy versus surgery alone were 47% and 29%, respectively. All patients who were treated with non-surgical therapy plus immunotherapy or non-surgical therapy alone died within 5 years of the diagnosis. Other prognostic factors assessed for an impact on survival included patient age at diagnosis, tumor size, FIGO stage, radicality of surgery, and lymphadenectomy performed during surgery. However, these factors were not significantly associated with survival in univariate analysis. Multivariate analysis identified cauliflower-like macroscopic tumor growth (hazard ratio \[HR\], 4.1; 95% confidence interval \[CI\], 1.4 to 12.1; p=0.010) and surgical treatment (HR, 0.3; 95% CI, 0.1 to 0.9; p=0.025) as significant poor and favorable prognostic factors for OS, respectively. These analyses are summarized in [Table 5](#T5){ref-type="table"}.

DISCUSSION
==========

Malignant melanoma of the vagina is a rare disease, especially in Asian women. In this study, the majority of patients were postmenopausal and their median age at diagnosis was 58 years. There were no cases of amelanotic vaginal melanoma. Of the vaginal melanomas, 18 (58%) were located in the lower third of the vagina, and most were nodular under gross observation. Furthermore, 84% were of FIGO stage I, whereas 10% and 7% were of stage II and stage IV, respectively. Overall, the characteristics of the subjects in this study are consistent with the patient characteristics described in previous reports of vaginal melanoma \[[@B3],[@B7]-[@B11]\].

In this study, we found that patients with cauliflower-like vaginal melanomas had the worst prognosis, whereas in contrast, those with ulcerative type tumors survived the longest. In previous studies, melanoma ulceration was associated with a worse prognosis due to the thickness and aggressiveness of the tumors \[[@B12]\]. However, ulceration has also been identified as a predictive marker for response to adjuvant IFN therapy \[[@B13]\]. In the present study, cauliflower-like tumors were typically large, and ulcerative type tumors had a better treatment response to immunotherapy. The sample size of the present study, especially for the ulcerative group, was relatively small. Therefore, these results need to be confirmed in a study with a larger sample size.

More aggressive surgeries have not been found to alter the prognosis of patients with vaginal melanomas \[[@B6],[@B10],[@B14],[@B15]\]. However, a high rate of local recurrence or local disease progression has been associated with conservative treatment approaches \[[@B11],[@B16]\]. In this study, no significant survival advantage was conferred by radical surgery, and indeed patients who underwent more conservative surgery survived longer than patients who underwent radical surgery. Therefore, on this basis, we suggest that a radical surgical approach including hysterectomy should be avoided for patients with early-stage vaginal melanoma, as it is unlikely to improve their prognosis. However, additional cases need to be examined to confirm this hypothesis because of the small sample size of the present study.

Currently, there is no general recommendation for the treatment of primary vaginal melanoma \[[@B6],[@B8],[@B14]\]. Melanoma is frequently considered a radioresistant tumor, and most reports favor surgery over primary radiotherapy \[[@B8]\]. Surgery has been associated with better clinical outcomes compared to chemotherapy approaches. In the present study, only a small number of patients received radiotherapy as their primary treatment, and this is consistent with previous reports \[[@B3],[@B7]-[@B11]\]. Immunotherapies recommended for stage II-IV melanoma according to the classification criteria of The American Joint Committee on Cancer (AJCC) include IFN-α, anti-GM2 antibodies, and IL-2 \[[@B17]-[@B19]\]. In the current study, IL-2, IFN-α, BCG, DC-cells, LAK cells, and a measles vaccine were administered to patients as immunotherapy agents. Patients who underwent surgery followed by immunotherapy attained the longest OS on average, among the 4 treatment groups. Further to these results, surgery followed by a postoperative immunotherapy regimen is recommended as the treatment protocol for patients with primary vaginal melanoma.

The 5-year OS rate for the 31 patients in this study was 32%. For patients who underwent surgical treatment, the 5-year OS rate was as high as 47%. This value is in the upper range of the 5-year survival rates previously reported for vaginal melanomas \[[@B1],[@B4]-[@B7]\]. In conclusion, the prognosis of patients with primary malignant melanoma of the vagina is poor. However, for patients with vaginal melanomas that are not cauliflower-like in shape, wide local excision followed by immunotherapy may improve prognosis.
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